Interaction between
Heparin
and
Oritavancin
Major
Antagonism
Basic Information
| ID | DDInter856 and DDInter1347 |
| Interaction | Use of oritavancin may interfere with the therapeutic monitoring of heparin therapy. Oritavancin can bind to and prevent the action of the phospholipid reagents that activate coagulation in commonly used laboratory coagulation tests. |
| Management | Use of intravenous unfractionated heparin is contraindicated for 120 hours (5 days) after oritavancin administration. For patients who require aPTT monitoring within 120 hours of oritavancin dosing, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered. |
| References | [1] "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ. |
| Alternative for Heparin |
B01A
|
| Alternative for Oritavancin |
J01X
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.